MRUS 42.93 (-1.29%)
NL0011606264BiotechnologyBiotechnology

Merus (MRUS) Stock Highlights

42.93 | -1.29%
2024-11-21 02:08:03
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.

Statistics

Range Today
42.3 43.52
Volume Today 605.27K
Range 1 Year
22.26 61.61
Volume 1 Year 166.36M
Range 3 Year
12.03 61.61
Volume 3 Year 316.38M
Range 10 Year
7.255 61.61
Volume 10 Year 446.12M

Highlights

Market Capitalization 3.73B (mid)
Floating Shares 62.88M
Current Price 42.93
Price To Earnings -13.47
Price To Revenue 86.55
Price To Book 5.3
Earnings Per Share -4.03
Payout Ratio 0%

Performance

Latest -1.29%
1 Month -18.04%
3 Months -20.03%
6 Months -2.14%
1 Year +76.59%
3 Years +51.16%
5 Years +172.23%
10 Years +340.31%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.